Satya R Khare1, Armen Aprikian2, Peter Black3, Normand Blais4, Chris Booth5, Fadi Brimo6, Joseph Chin7, Peter Chung8, Darrel Drachenberg9, Libni Eapen10, Adrian Fairey11, Neil Fleshner12, Yves Fradet13, Geoffrey Gotto14, Jonathan Izawa7, Michael Jewett12, Girish Kulkarni12, Louis Lacombe13, Ron Moore11, Chris Morash15, Scott North16, Ricardo Rendon17, Fred Saad18, Bobby Shayegan19, Robert Siemens20, Alan So3, Srikala S Sridhar21, Samer L Traboulsi2, Wassim Kassouf22. 1. Department of Family Medicine, McGill University, Montreal, QC, Canada. 2. Department of Urology, McGill University Health Centre, Montreal, QC, Canada. 3. Department of Urology, University of British Columbia, Vancouver, BC, Canada. 4. Division of Medical Oncology, University of Montreal, Montreal, QC, Canada. 5. Department of Oncology, Queen's University, Kingston, ON, Canada. 6. Department of Pathology, McGill University Health Centre, Montreal, QC, Canada. 7. Division of Urology, Western University, London, ON, Canada. 8. Department of Radiation Oncology, Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON, Canada. 9. Division of Urology, University of Manitoba, Winnipeg, MB, Canada. 10. Division of Radiation Oncology, University of Ottawa, Ottawa, ON, Canada. 11. Division of Urology, University of Alberta, Edmonton, AB, Canada. 12. Departments of Surgery (Urology), Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada; Department of Surgical Oncology, Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada. 13. Division of Urology, Laval University, Quebec City, QC, Canada. 14. Division of Urology, University of Calgary, Calgary, AB, Canada. 15. Division of Urology, University of Ottawa, Ottawa, ON, Canada. 16. Division of Medical Oncology, University of Alberta, Edmonton, AB, Canada. 17. Division of Urology, Dalhousie University, Halifax, NS, Canada. 18. Division of Urology, University of Montreal, QC, Canada. 19. Division of Urology, McMaster University, Hamilton, ON, Canada. 20. Department of Oncology, Queen's University, Kingston, ON, Canada; Department of Urology, Queen's University, Kingston, ON, Canada. 21. Department of Medical Oncology, Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON, Canada. 22. Department of Urology, McGill University Health Centre, Montreal, QC, Canada. Electronic address: wassim.kassouf@muhc.mcgill.ca.
Abstract
BACKGROUND: Survival in patients with bladder cancer has only moderately improved over the past 2 decades. A potential reason for this is nonadherence to clinical guidelines and best practice, leading to wide variations in care. Common quality indicators (QIs) are needed to quantify adherence to best practice and provide data for benchmarking and quality improvement. OBJECTIVE: To produce an evidence- and consensus-based list of QIs for the management of bladder cancer. METHODS: A modified Delphi method was used to develop the indicator list. Candidate indicators were extracted from the literature and rated by a 27-member Canadian expert panel in several rounds until consensus was reached on the final list of indicators. In rounds with numeric ratings, a frequency analysis was performed. RESULTS: A total of 86 indicators were rated, 52 extracted from the literature and 34 suggested by the panel. After iterative rounds of ratings and discussion, a final list of 60 QIs spanning several disciplines and phases of the cancer care continuum was developed. CONCLUSIONS: This is the first study to comprehensively produce common QIs representing structure, process, and outcome measures in bladder cancer management. Though developed in Canada, these indicators can be used in other countries with slight modifications to track performance and improve care.
BACKGROUND: Survival in patients with bladder cancer has only moderately improved over the past 2 decades. A potential reason for this is nonadherence to clinical guidelines and best practice, leading to wide variations in care. Common quality indicators (QIs) are needed to quantify adherence to best practice and provide data for benchmarking and quality improvement. OBJECTIVE: To produce an evidence- and consensus-based list of QIs for the management of bladder cancer. METHODS: A modified Delphi method was used to develop the indicator list. Candidate indicators were extracted from the literature and rated by a 27-member Canadian expert panel in several rounds until consensus was reached on the final list of indicators. In rounds with numeric ratings, a frequency analysis was performed. RESULTS: A total of 86 indicators were rated, 52 extracted from the literature and 34 suggested by the panel. After iterative rounds of ratings and discussion, a final list of 60 QIs spanning several disciplines and phases of the cancer care continuum was developed. CONCLUSIONS: This is the first study to comprehensively produce common QIs representing structure, process, and outcome measures in bladder cancer management. Though developed in Canada, these indicators can be used in other countries with slight modifications to track performance and improve care.
Authors: Madhuri Koti; David M Berman; D Robert Siemens; Dirk Lange; Edwin Wang; Paul Toren; Bernhard J Eigl; Céline Hardy; Robert Purves; Vincent Fradet; Yves Fradet; Jose Mansure; Wassim Kassouf; Peter C Black Journal: Can Urol Assoc J Date: 2020-10 Impact factor: 1.862
Authors: Wassim Kassouf; Armen Aprikian; Fred Saad; Rodney H Breau; Girish Kulkarni; David M Guttman; Ken Bagshaw; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Fadi Brimo; Peter Chung; Darrel Drachenberg; Yves Fradet; Niels Jacobsen; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Alex Zlotta; Neil Fleshner; D Robert Siemens; Peter C Black Journal: Can Urol Assoc J Date: 2018-03-19 Impact factor: 1.862
Authors: Peter C Black; Nimira Alimohamed; Wassim Kassouf; John L Gore; Kathy D McCoy; Brad H Nelson; Daniel D De Carvalho; Rodney J Ouellette; Ferg Devins; Tony Cornacchia; D Robert Siemens; David M Berman; Srikala S Sridhar; Girish Kulkarni Journal: Can Urol Assoc J Date: 2022-06 Impact factor: 2.052
Authors: Misa Matsuyama; Mythily Sachchithananthan; Robyn Leonard; Michael Besser; Anna K Nowak; Donna Truran; Claire M Vajdic; John R Zalcberg; Hui K Gan; Craig Gedye; Winny Varikatt; Eng-Siew Koh; Ganessan Kichenadasse; Hao-Wen Sim; Nicholas G Gottardo; Desma Spyridopoulos; Rosalind L Jeffree Journal: Neurooncol Pract Date: 2021-08-31
Authors: Murat Akand; Tim Muilwijk; Jan Cornelissen; Siska Van Bruwaene; Kathy Vander Eeckt; Frederic Baekelandt; Pieter Mattelaer; Raf Van Reusel; Ben Van Cleynenbreugel; Steven Joniau; Frank Van Der Aa Journal: Front Oncol Date: 2019-12-11 Impact factor: 6.244
Authors: Antonín Brisuda; James C S Ho; Pancham S Kandiyal; Justin T-Y Ng; Ines Ambite; Daniel S C Butler; Jaromir Háček; Murphy Lam Yim Wan; Thi Hien Tran; Aftab Nadeem; Tuan Hiep Tran; Anna Hastings; Petter Storm; Daniel L Fortunati; Parisa Esmaeili; Hana Novotna; Jakub Horňák; Y G Mu; K H Mok; Marek Babjuk; Catharina Svanborg Journal: Nat Commun Date: 2021-06-08 Impact factor: 14.919